Cargando…

Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma

OBJECTIVE: Assessing plasma Cell Free DNA (cfDNA) integrity index as a biomarker for response prediction and early response evaluation in mCRC patients receiving chemotherapy, in comparison to Carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9), to be used as an additional tool to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eskander, Nancy Samir, Mansour, Lamia, Abdelaal, Amaal, Saad, Ehab, Mohamed, Doaa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258663/ https://www.ncbi.nlm.nih.gov/pubmed/35092403 http://dx.doi.org/10.31557/APJCP.2022.23.1.339

Ejemplares similares

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options
por: Hummel, Michael, et al.
Publicado: (2021)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
por: Pastor, Brice, et al.
Publicado: (2021)

Effect of magnesium sulphate on bi-spectral index (BIS) values during general anesthesia in children
por: Amer, Mahmoud Mostafa, et al.
Publicado: (2015)

Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer
por: Rasmussen, Louise, et al.
Publicado: (2017)

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
por: Osumi, Hiroki, et al.
Publicado: (2020)

Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection
por: Mansour, Hicham
Publicado: (2014)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Effect of exercise therapy on physical performance and functional balance in patients on maintenance renal hemodialysis: randomized controlled study
por: Abdelaal, Ashraf Abdelaal Mohamed, et al.
Publicado: (2019)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Cell-free circulating tumor RNAs in plasma as the potential prognostic biomarkers in colorectal cancer
por: Jin, Nana, et al.
Publicado: (2023)

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA
por: Berger, Andreas W., et al.
Publicado: (2017)

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2019)

Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer
por: Jia, Ning, et al.
Publicado: (2021)

Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
por: de Takats, P. G., et al.
Publicado: (1994)

Circulating prostaglandins as biomarkers for colorectal cancer?
por: Greenhough, Alexander, et al.
Publicado: (2015)

Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers
por: Gherman, Alexandra, et al.
Publicado: (2020)

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
por: Raunkilde, Louise, et al.
Publicado: (2022)

Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer
por: Hao, T B, et al.
Publicado: (2014)

Genome-wide discovery of circulating cell-free DNA methylation biomarkers for colorectal cancer detection
por: Fang, Qingxiao, et al.
Publicado: (2023)

Anticandidal Potential of Two Cyanobacteria-Synthesized Silver Nanoparticles: Effects on Growth, Cell Morphology, and Key Virulence Attributes of Candida albicans
por: Hamida, Reham Samir, et al.
Publicado: (2021)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab
por: Nissen, Neel I., et al.
Publicado: (2021)

Circulating guanylyl cyclase C (GCC) mRNA is a reliable metastatic predictor and prognostic index of colorectal cancer
por: Jiang, Lai, et al.
Publicado: (2020)

Prolonged survival in metastatic colorectal cancer following chemotherapy
por: Paul, Doru, et al.
Publicado: (2014)

Use of perioperative chemotherapy in colorectal cancer metastatic to the liver
por: Symonds, Lynn K, et al.
Publicado: (2019)

Management of chemotherapy dose intensity for metastatic colorectal cancer
por: Chu, Xuelei, et al.
Publicado: (2022)

Decreased Circulating T Regulatory Cells in Egyptian Patients with Nonsegmental Vitiligo: Correlation with Disease Activity
por: Hegab, Doaa Salah, et al.
Publicado: (2015)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients
por: Galbiati, Silvia, et al.
Publicado: (2021)

Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
por: Mahmood, Reem D., et al.
Publicado: (2021)

LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer
por: Nagai, Yuzo, et al.
Publicado: (2017)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
por: Xu, Xiaojing, et al.
Publicado: (2020)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
por: Salvianti, Francesca, et al.
Publicado: (2021)

Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer
por: Hansen, T F, et al.
Publicado: (2015)

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
por: Yao, Jiannan, et al.
Publicado: (2018)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

Prognostic value of circulating endothelial cells in metastatic colorectal cancer
por: Rahbari, Nuh N, et al.
Publicado: (2017)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Lethal Mechanisms of Nostoc-Synthesized Silver Nanoparticles Against Different Pathogenic Bacteria
por: Hamida, Reham Samir, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g389eib5d7d566f25d151o8djk